MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. announced that their Boards of Directors resolved an execution of Memorandum on granting of exclusive negotiation rights for the global commercialization outside Japan of four new drug candidates being developed by JCR for ultra-rare lysosomal storage diseases (LSDs) (hereinafter, "the Memorandum"). Furthermore, in accordance with the execution
of Memorandum, the two companies have concluded a licensing agreement for a therapeutic candidate for the treatment of fucosidosis.